Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Glaucoma Market Expected To Grow In Terms Of Size?

The market size for glaucoma has seen substantial growth over the recent years. Its worth shall escalate from $7.76 billion in 2024 to $8.2 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The growth experienced in the past can be attributed to heightened awareness regarding eye health, increased healthcare expenditure, a rise in the adoption of telemedicine for eye care, expanded healthcare infrastructure and growth in government health initiatives.

The market size for glaucoma is projected to experience significant expansion in the coming years, escalating to a value of $10.12 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.4%. Factors contributing to the growth for this period include an aging population, increased cases of glaucoma, a rising demand for procedures that are minimally invasive, an increased diabetes prevalence, and higher hypertension rates. Key trends for this forecast period encompass enhancements in diagnostic technologies, new drug treatments becoming available, technological evolution in surgical instruments, availability of combined therapies, and the uptake of robotic surgeries.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What Market Forces Are Contributing To The Growth Of The Glaucoma Market?

An increase in chronic eye disorders is anticipated to fuel the expansion of the glaucoma market. Chronic eye disorders are enduring issues that impact the eyes, often resulting in persistent vision loss or discomfort, thereby necessitating continuous management or treatment. The escalation of chronic eye disorders is a result of aging populations, prolonged screen exposure, lifestyle habits, and an increased occurrence of diseases such as diabetes and hypertension. Treatment for glaucoma is needed to reduce intraocular pressure, avert further optic nerve deterioration, and retain vision, as unmanaged glaucoma can culminate in irreversible blindness. For example, in December 2024, the National Health Service (NHS), a publicly funded healthcare system based in the UK, reported that over 2 million people in the UK were living with vision loss. Moreover, the number of people experiencing vision loss is predicted to grow by 27%, reaching approximately 2.8 million by 2035. Hence, the growing prevalence of chronic eye disorders is fueling the glaucoma market.

How Is The Glaucoma Market Segmented Across Key Categories?

The glaucomamarket covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types

2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy

3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes

4) By Administration: Oral; Injections; Intravitreal; Other Administrations

5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma

What Key Trends Are Driving Growth In The Glaucoma Market?

Top firms in the glaucoma market are concentrating on the creation of novel therapies, namely Rho-kinase (ROCK) inhibitors. These provide a two-fold action method, reducing the intraocular pressure via improved aqueous humor outflow and trabecular meshwork cells relaxation, suggesting their effectiveness in glaucoma treatment. These ROCK inhibitors are a group of medicines that obstruct the Rho-kinase enzymes function, which control cell contraction and reduce intraocular pressure as part of glaucoma treatment. For instance, Santen Pharmaceutical Co. Ltd., an eye care company based in Japan, introduced Roclanda in the UK back in July 2023. Roclanda is a combined fixed dose of latanoprost and netarsudil, an innovative Rho-kinase (ROCK) inhibitor, that effectively curbs intraocular pressure (IOP) by dealing with trabecular meshwork dysfunction. It is aimed for adult patients with primary open-angle glaucoma or ocular hypertension who didn’t obtain sufficient IOP reduction with prostaglandin or netarsudil monotherapy. The Roclanda introduction in Europe represents the first new glaucoma drug class in 25 years, signifying a significant treatment advancement. With the fusion of netarsudil and latanoprost, Roclanda collaboratively increases the outflow via trabecular (traditional) and uveoscleral (non-traditional) routes, offering an inclusive approach to elevated IOP management.

Who Are The Major Stakeholders Operating In The Glaucoma Market?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

How Do Regional Dynamics Influence The Glaucoma Market Performance?

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

Browse Through More Reports Similar to the Global Glaucoma Market 2025, By The Business Research Company

Antiglaucoma Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Glaucoma Surgery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glaucoma-surgery-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model